Janux Therapeutics
JANX
174 hedge funds and large institutions have $1.51B invested in Janux Therapeutics in 2025 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 80 increasing their positions, 54 reducing their positions, and 22 closing their positions.
48% more repeat investments, than reductions
Existing positions increased: 80 | Existing positions reduced: 54
34% more call options, than puts
Call options by funds: $20.2M | Put options by funds: $15.1M
1.86% less ownership
Funds ownership: 112.47% → 110.61% (-1.9%)
4% less funds holding
Funds holding: 181 → 174 (-7)
16% less capital invested
Capital invested by funds: $1.81B → $1.51B (-$292M)
27% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 22
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$46.6M |
| 2 |
BlackRock
New York
|
+$14M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$13.8M |
| 4 |
O
OrbiMed
New York
|
+$11.9M |
| 5 |
RAM
Readystate Asset Management
Chicago,
Illinois
|
+$11.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$29.8M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$18M |
| 3 |
PA
Perceptive Advisors
New York
|
-$17.9M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$17.1M |
| 5 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$13.4M |
JANX Hedge Fund Activity: Q2 2025 in Review
174 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Janux Therapeutics (JANX) for Q2 2025, worth a combined $1.51B — down 16% from $1.81B a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of JANX and 16 opened new positions — a net loss of 6 holders — while 54 trimmed existing stakes and 80 added.
The largest buyer was Point72 Asset Management, adding an estimated $46.6M. The largest seller was Adage Capital Partners, cutting an estimated $29.8M.
- 174 institutional investors held Janux Therapeutics (JANX) as of Q2 2025, down from 181 in Q1 2025.
- Funds reported $1.51B of Janux Therapeutics stock for Q2 2025, down 16% quarter-over-quarter.
- 16 funds opened new Janux Therapeutics positions in Q2 2025 and 22 closed out, a net change of -6 holders.
- The largest Janux Therapeutics buyer in Q2 2025 was Point72 Asset Management, an estimated $46.6M added.
- The largest Janux Therapeutics seller in Q2 2025 was Adage Capital Partners, an estimated $29.8M sold.
Based on aggregated 13F filings for Q2 2025.